Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.52 |
| ▸ | CASP3 | P42574 | 2/20 | 0.33 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.33 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.33 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 3/20 | 0.32 |
| ▸ | MAPT | P10636 | 3/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 3/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7656479 | 0.77 | DAO (0.63) | DAOCASP3SENP7SENP8SENP6 | |
| SCHEMBL131369 | 0.76 | DAO (0.67) | DAOCASP3SENP7SENP8SENP6 | |
| SCHEMBL14269794 | 0.74 | DAO (0.59) | DAOCASP3SENP7SENP8SENP6 | |
| SCHEMBL28752248 | 0.74 | DAO (0.59) | DAOCASP3SENP7SENP8SENP6 | |
| SCHEMBL5279649 | 0.73 | MMP12 (0.44) | — | |
| SCHEMBL6826976 | 0.73 | DAO (0.57) | DAOMEN1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL5289722 | 0.72 | DAO (0.36) | DAOMEN1MAPTKMT2ALMNA | |
| SCHEMBL5889493 | 0.72 | HDAC4 (0.42) | DAOCASP3SENP7SENP8SENP6 | |
| SCHEMBL5292745 | 0.71 | DAO (0.55) | DAOCASP3SENP7SENP8SENP6 | |
| SCHEMBL27780583 | 0.71 | DAO (0.55) | DAOCASP3SENP7SENP8SENP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007001335-A2 | RAMOPLANIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20060211603-A1 | Ramoplanin derivatives possessing antibacterial activity | VICURON PHARMACEUTICALS INC. (US) | 2006-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211603-A1 | Ramoplanin derivatives possessing antibacterial activity | CLSPN, LMAN2, RPN2 | DAO 1438/4885CASP3 2634/4885SENP7 1754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.